FDA official denies politics delaying Plan B decision

Share this article:
The FDA’s acting director refuted concerns that politics are delaying the agency’s review of an OTC switch petition for Plan B, the AP reports. Andrew von Eschenbach told House members that the decision on the morning-after contraceptive pill, marketed by Barr Labs, would be based on science. "That process will be carried out in the appropriate fashion," he said, while appearing before a House Appropriations subcommittee to go over the agency's budget. House Democrats pressed von Eschenbach on the issue, saying the agency has had ample time to reach a decision. Under Barr’s revised application—the FDA rejected its initial OTC petition in 2004—Plan B would become available over the counter to patients 16 and above but remain a prescription drug for younger ones. Those age limits create a novel situation for the FDA, which has not considered the same product as both a prescription and OTC drug. Von Eschenbach declined to say when the agency might rule, adding that it was reviewing public comment.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.